IL-22, currently in clinical trials for IBD, exhibits antipsychotic-like properties and promotes thymus gland rejuvenation, suggesting beneficial effects in SCZ (NCT02847052) [302,303,304,305]. The gene discussed is IL22; the disease is inflammatory bowel disease.